| 12/6/2019 | BKIG | Moody’s lifts Celgene debt
|
| 11/21/2019 | BKIG | S&P boosts Celgene, off watch
|
| 1/4/2019 | BKIG | S&P puts Celgene on positive watch
|
| 1/3/2019 | BKCV | Moody's puts Celgene on upgrade review
|
| 1/3/2019 | BK | Bristol-Myers Squibb to use debt financing for Celgene acquisition
|
| 4/30/2018 | BK | Celgene enters five-year $2 billion amended and restated revolver
|
| 2/8/2018 | BKIG | Moody’s rates Celgene notes Baa2
|
| 2/8/2018 | BKIG | S&P rates Celgene notes BBB+
|
| 1/22/2018 | BKIG | S&P affirms Celgene
|
| 1/22/2018 | BKIG | Moody’s affirms Celgene
|
| 10/31/2017 | BKIG | S&P rates Celgene notes BBB+
|
| 10/31/2017 | BKIG | Moody’s gives Baa2 to Celgene notes
|
| 8/1/2017 | BKIG | S&P gives BBB+ to Celgene notes
|
| 8/1/2017 | BKIG | Moody’s rates Celgene notes Baa2
|
| 4/18/2016 | BK | Celgene extends revolver one year, increases commitment to $2 billion
|
| 10/19/2015 | BK | Celgene enters into $1 billion revolving agreement through year’s end
|
| 8/3/2015 | BKIG | S&P rates Celgene notes BBB+
|
| 8/3/2015 | BKIG | Moody’s cuts Celegene, rates notes Baa2
|
| 7/15/2015 | BKIG | Celgene gets commitment for $5 billion bridge loan to finance merger
|
| 7/15/2015 | BKIG | S&P lowers Celgene to stable
|
| 7/15/2015 | BKIG | Moody’s could drop Celgene
|
| 4/21/2015 | BKIG | Moody's upgrades Celgene
|
| 4/20/2015 | BK | Celgene increases revolver to $1.75 billion, extends term by two years
|
| 6/12/2014 | BKIG | S&P lifts Celgene to positive
|
| 5/6/2014 | BKIG | S&P assigns Celgene notes BBB+
|
| 5/6/2014 | BKIG | Moody's gives Celgene notes Baa2
|
| 8/1/2013 | BKIG | Moody's rates Celgene notes Baa2
|
| 8/1/2013 | BKIG | S&P rates Celgene notes BBB+
|
| 6/12/2013 | BKIG | Moody's: Celgene view to positive
|
| 4/19/2013 | BK | Celgene increases revolver to $1.5 billion, extends maturity to 2018
|
